IPAD-DB ID | C00237 |
Name | Ladostigil |
Category | Natural compounds |
2D Structure |
|
3D Structure | |
Molecular Formula | C 1 6 H 2 0 N 2 O 2 |
Molecular Weight | 272.34 g/mol |
IUPAC Name | [(3R)-3-(prop-2-ynylamino)-2, 3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate |
InChI | InChI=1S/C16H20N2O2/c1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2/h1, 6, 8, 11, 15, 17H, 5, 7, 9-10H2, 2-3H3/t15-/m1/s1 |
InChIKey | LHXOCOHMBFOVJS-OAHLLOKOSA-N |
Canonical SMILES | CCN(C)C(=O)OC1=CC2=C(CCC2NCC#C)C=C1 |
PubChem CID | 208907 |
DrugBank Accession Number | DB16213 |
CAS Registry Number | 209394-27-4 |
Molecular Weight(Computed by SwissADME) | 272.34 |
Hac(Computed by SwissADME) | 20 |
Volume(Computed by ADMETlab 2.0) | 291.935 |
Density(Computed by ADMETlab 2.0) | 0.932 |
nRing(Computed by ADMETlab 2.0) | 2 |
MaxRing(Computed by ADMETlab 2.0) | 9 |
nHet(Computed by ADMETlab 2.0) | 4 |
fChar(Computed by ADMETlab 2.0) | 0 |
nRig(Computed by ADMETlab 2.0) | 12 |
Flexibility(Computed by ADMETlab 2.0) | 0.5 |
Stero Centers(Computed by ADMETlab 2.0) | 1 |
LogS(Computed by ADMETlab 2.0) | -1.53 |
LogD(Computed by ADMETlab 2.0) | 1.917 |
logP(Computed by ADMETlab 2.0) | 2.274 |
TPSA(Computed by SwissADME) | 41.57 |
Hbond Acceptor(Computed by SwissADME) | 3 |
Hbond Donor(Computed by SwissADME) | 1 |
Rotatable Bonds(Computed by SwissADME) | 6 |
GI Absorption(Computed by SwissADME) | High |
BBB(blood-brain barrier) Permeant(Computed by SwissADME) | Yes |
P-gp Substrate(Computed by SwissADME) | No |
CYP1A2 Inhibitor(Computed by SwissADME) | No |
CYP2C19 Inhibitor(Computed by SwissADME) | No |
CYP2C9 Inhibitor(Computed by SwissADME) | No |
CYP2D6 Inhibitor(Computed by SwissADME) | Yes |
CYP3A4 Inhibitor(Computed by SwissADME) | No |
log Kp(Skin Permeation)(Computed by SwissADME) | -6.57 |
Lipinski(Computed by SwissADME) | 0 |
Ghose(Computed by SwissADME) | 0 |
Veber(Computed by SwissADME) | 0 |
Egan(Computed by SwissADME) | 0 |
Muegge(Computed by SwissADME) | 0 |
Bioavailability Score(Computed by SwissADME) | 0.55 |